Jacob Stuckey
Vice President, Biochemistry & Chemical Biology Flare Therapeutics
Jake is passionate about blending mechanistic biochemistry with state-of-the-art drug discovery and chemical biology approaches. One of the architects of the Switch Site Framework, Jake is excited to help empower the team to discover the next wave of transcription factor medicines.
He has contributed to multiple clinical stage drug discovery efforts, including co-invention of Tulmimetostat and FX-909.
Seminars
As covalent programs mature, early warhead design decisions increasingly determine whether compounds progress or stall during translation. This workshop will examine how chemistry choices interact with PK/PD behavior, developability constraints and translational expectations, helping teams design warheads that remain viable through optimization and into IND enabling studies.
This session will address:
• Exploring non-acrylamide chemotypes and beyond to evaluate how alternative warhead chemistries electrophiles, alongside electrophile choice, placement, and scaffold context drive covalent engagement and selectivity
• Leveraging chemoproteomics and cellular covalent screening to profile target engagement and proteome-wide reactivity, enabling data-driven optimization and prioritization of warhead strategies
• Learning from real-world case studies, including deprioritized programs to uncover key pitfalls, unexpected liabilities, and transferable insights that improve decision making and reduce late-stage risk
